Quality Improvement PrecivityAD Clinician Survey (QUIP I)

There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Cognition Disorders Cognitive Decline Cognitive Dysfunction Dementia Mental Disorders Mild Cognitive Impairment Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

C2N Diagnostics

St Louis, Missouri, 63110, United States

About this study

By gathering feedback from healthcare providers on patient selection, intended use, and anticipated outcomes and continued or revised care plans as a result of the test report, C2N can better understand the impact of the test results on diagnosis and patient management.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Memory specialist actively practicing in the United States.
Practice includes individuals with mild cognitive impairment age > 60 years
Average patient volume > 50 visits per week (all patients seen across practice)

Exclusion criteria

Other clinicians with a specialty outside of the field of Memory Specialists
Principal Investigator reserves the right to not include a clinician in the survey

Treatment and study plan

PrecivityAD blood test

Other

Clinician Survey post receipt of PrecivityAD blood test result

Other names: AD

Primary outcomes

evaluate patient selection for the blood test through analysis of clinician survey responses.

Time frame: 2021 - 2023

retrospective analysis of clinician survey data collected during a single timepoint
evaluate score interpretation for the Amyloid Probability Score (APS) through analysis of clinician survey responses.

Time frame: 2021 - 2023

retrospective analysis of clinician survey data collected during a single timepoint

Sponsors and collaborators

Lead sponsor

C2N Diagnostics

Industry

Registry information

Official study title

Quality Improvement Survey I.0: A Retrospective Data Analysis of Clinician Survey Responses Following the Utilization of the PrecivityADTM Blood Test for the Detection of Alzheimer's Disease Pathology (QUIP I)

Acronym: QUIP I

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Jul 28, 2022
Registry last updated: Feb 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed